Abbbott to acquire Bigfooot Biomedical and with it Bigfoot Unity smart insulin management system
Abbott and Bigfoot Biomedical announced a definitive agreement for Abbott to acquire Bigfoot, a leader in developing smart insulin management systems for people with diabetes. The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2023.
Financial terms were not disclosed. Abbott and Bigfoot have worked together on connected diabetes solutions since 2017. Bigfoot developed Bigfoot Unity, a smart insulin management system that features the first and only FDA-cleared connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data along with healthcare provider instructions to provide insulin dosing recommendations. The dosing recommendations are displayed on the pen cap’s digital screen to help people know how much insulin to take. The Bigfoot Unity system exclusively works with Abbott’s world-leading FreeStyle Libre technology and includes a customer smartphone app connected to a cloud-based online portal used by healthcare providers to support their patients, including through remote care.
Related news and insights
Alfasigma S.p.A , one of Italy's leading pharmaceutical companies, and Intercept Pharmaceuticals, Inc., a leading biopharmaceutical company in rare and serious liver diseases, announced that they have entered into a definitive merger agreement under which Alfasigma has agreed to acquire Intercept for $19.00 per share in cash
Bayer and Hologic, Inc., announced an international partnership to deliver contrast-enhanced-mammography (CEM) solutions to improve the detection of breast cancer in multiple countries across Canada, the European and Asia Pacific regions